Literature DB >> 28885433

Put away your microscopes: the ependymoma molecular era has begun.

Stephen C Mack1, Michael D Taylor.   

Abstract

PURPOSE OF REVIEW: To synthesize, integrate, and comment on recent research developments to our understanding of the molecular basis of ependymoma (EPN), and to place this in context with current treatment and research efforts. RECENT
FINDINGS: Our recent understanding of the histologically defined molecular entity EPN has rapidly advanced through genomic, transcriptomic, and epigenomic profiling studies.
SUMMARY: These advancements lay the groundwork for development of future EPN biomarkers, models, and therapeutics. Our review discusses these discoveries and their impact on our clinical understanding of this disease. Lastly, we offer insight into clinical and research areas requiring further validation, and open questions remaining in the field.

Entities:  

Mesh:

Year:  2017        PMID: 28885433      PMCID: PMC6003664          DOI: 10.1097/CCO.0000000000000411

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  30 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

Review 2.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.

Authors:  Randy Johnson; Georg Halder
Journal:  Nat Rev Drug Discov       Date:  2013-12-13       Impact factor: 84.694

3.  A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.

Authors:  Till Milde; Susanne Kleber; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Philipp Koch; Hans-Georg Kopp; Manfred Jugold; Hedwig E Deubzer; Ina Oehme; Marco Lodrini; Hermann-Josef Gröne; Axel Benner; Oliver Brüstle; Richard J Gilbertson; Andreas von Deimling; Andreas E Kulozik; Stefan M Pfister; Ana Martin-Villalba; Olaf Witt
Journal:  Acta Neuropathol       Date:  2011-08-24       Impact factor: 17.088

4.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

6.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

7.  Radial glia cells are candidate stem cells of ependymoma.

Authors:  Michael D Taylor; Helen Poppleton; Christine Fuller; Xiaoping Su; Yongxing Liu; Patricia Jensen; Susan Magdaleno; James Dalton; Christopher Calabrese; Julian Board; Tobey Macdonald; Jim Rutka; Abhijit Guha; Amar Gajjar; Tom Curran; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

8.  A prognostic gene expression signature in infratentorial ependymoma.

Authors:  Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape
Journal:  Acta Neuropathol       Date:  2012-02-10       Impact factor: 17.088

Review 9.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

10.  C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

Authors:  Matthew Parker; Kumarasamypet M Mohankumar; Chandanamali Punchihewa; Ricardo Weinlich; James D Dalton; Yongjin Li; Ryan Lee; Ruth G Tatevossian; Timothy N Phoenix; Radhika Thiruvenkatam; Elsie White; Bo Tang; Wilda Orisme; Kirti Gupta; Michael Rusch; Xiang Chen; Yuxin Li; Panduka Nagahawhatte; Erin Hedlund; David Finkelstein; Gang Wu; Sheila Shurtleff; John Easton; Kristy Boggs; Donald Yergeau; Bhavin Vadodaria; Heather L Mulder; Jared Becksfort; Jared Becksford; Pankaj Gupta; Robert Huether; Jing Ma; Guangchun Song; Amar Gajjar; Thomas Merchant; Frederick Boop; Amy A Smith; Li Ding; Charles Lu; Kerri Ochoa; David Zhao; Robert S Fulton; Lucinda L Fulton; Elaine R Mardis; Richard K Wilson; James R Downing; Douglas R Green; Jinghui Zhang; David W Ellison; Richard J Gilbertson
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962

View more
  10 in total

1.  Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.

Authors:  Bahattin Tanrıkulu; Ayça Erşen Danyeli; M Memet Özek
Journal:  Childs Nerv Syst       Date:  2020-02-05       Impact factor: 1.475

2.  Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling.

Authors:  Ross Mangum; Jacquelyn Reuther; Kelsey C Bertrand; Raghu Chandramohan; Marcia K Kukreja; Arnold C Paulino; Donna Muzny; Jianhong Hu; Richard A Gibbs; Daniel J Curry; Fatema Malbari; Murali M Chintagumpala; Adekunle M Adesina; Kevin E Fisher; Stephen C Mack; Sharon E Plon; Angshumoy Roy; D Williams Parsons; Frank Y Lin
Journal:  JCO Precis Oncol       Date:  2021-07-28

3.  Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.

Authors:  Lorena V Baroni; Lakshmikirupa Sundaresan; Ayala Heled; Hallie Coltin; Kristian W Pajtler; Tong Lin; Thomas E Merchant; Roger McLendon; Claudia Faria; Molly Buntine; Christine L White; Stefan M Pfister; Mark R Gilbert; Terri S Armstrong; Eric Bouffet; Sachin Kumar; Michael D Taylor; Kenneth D Aldape; David W Ellison; Nicholas G Gottardo; Marcel Kool; Andrey Korshunov; Jordan R Hansford; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

4.  New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X.

Authors:  Lorena Favaro Pavon; David Capper; Tatiana Tais Sibov; Silvia Regina Caminada de Toledo; Ulrich-W Thomale; Jean Gabriel de Souza; Francisco Romero Cabral; Carolina Maria Berra; Marcos Devanir Silva da Costa; Jardel Mendonça Niçacio; Patrícia Alessandra Dastoli; Daniela Mara de Oliveira; Suzana M F Malheiros; Edgar Ferreira da Cruz; Jackeline Moraes Malheiros; Sérgio Mascarenhas de Oliveira; Nasjla Saba Silva; Antonio Sérgio Petrilli; Andrea Maria Cappellano; Milena Colò Brunialti; Reinaldo Salomão; Manoel A de Paiva Neto; Ana Marisa Chudzinski-Tavassi; Sérgio Cavalheiro
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

5.  DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.

Authors:  Nasim Azizgolshani; Curtis L Petersen; Youdinghuan Chen; Joshua J Levy; Lucas A Salas; Laurent Perreard; Lananh N Nguyen; Brock C Christensen
Journal:  Clin Epigenetics       Date:  2021-09-19       Impact factor: 6.551

Review 6.  Citation analysis of the most influential ependymoma research articles illustrates improved knowledge of the molecular biology of ependymoma.

Authors:  Nolan J Brown; Bayard Wilson; Brian V Lien; Alexander Himstead; Ali R Tafreshi; Shane Shahrestani; Jack Birkenbeuel; Katelynn Tran; David Horton; Anushka Paladugu; Lydia R Kirillova; Chen Yi Yang; Seth C Ransom; Ronald Sahyouni; Isaac Yang
Journal:  Neurosurg Rev       Date:  2021-10-06       Impact factor: 3.042

Review 7.  Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.

Authors:  Mary Jane Lim-Fat; Maria Macdonald; Sarah Lapointe; Seth Andrew Climans; Chantel Cacciotti; Manik Chahal; Sebastien Perreault; Derek S Tsang; Andrew Gao; Stephen Yip; Julia Keith; Julie Bennett; Vijay Ramaswamy; Jay Detsky; Uri Tabori; Sunit Das; Cynthia Hawkins
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

8.  Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016.

Authors:  Rebecca L Achey; Sierra Vo; Gino Cioffi; Haley Gittleman; Julia Schroer; Vishesh Khanna; Robin Buerki; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2020-05-09

Review 9.  Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.

Authors:  Manon Douyère; Pascal Chastagner; Cédric Boura
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

Review 10.  Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era.

Authors:  Tae-Young Jung; Shin Jung; Hoon Kook; Hee-Jo Baek
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.